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Background: Diabetes is associated with a high incidence of macrovascular disease (MVD), including peripheral
and coronary artery disease. Circulating soluble-Klotho (sKlotho) is produced in the kidney and is a putative
anti-aging and vasculoprotective hormone. Reduced Klotho levels may therefore increase cardiovascular risk in
diabetes. We investigated if sKlotho levels are decreased in type 2 diabetes and associate with MVD in the absence
of diabetic nephropathy, and whether hyperglycemia affects renal Klotho production in vitro and in vivo.
Methods: sKlotho levels were determined with ELISA in diabetic and non-diabetic patients with and without MVD,
and healthy control subjects. Human renal tubular epithelial cells (TECs) were isolated and exposed to high glucose
levels (15 and 30 mM) in vitro and Klotho levels were measured with qPCR and quantitative immunofluorescence.
Klotho mRNA expression was quantified in kidneys obtained from long term (3 and 8 months) diabetic Ins2Akita
mice and normoglycemic control mice.
Results: No significant differences in sKlotho levels were observed between diabetic patients with and without
MVD (527 (433–704) pg/mL, n = 35), non-diabetic MVD patients (517 (349–571) pg/mL, n = 27), and healthy control
subjects (435 (346–663) pg/mL, n = 15). High glucose (15 and 30 mM) did not alter Klotho expression in TECs.
Long-term hyperglycemia in diabetic Ins2Akita mice (characterized by increased HbA1c levels [12.9 ± 0.3% (3 months)
and 11.3 ± 2.0% (8 months)], p < 0.05 vs. non-diabetic mice) did not affect renal Klotho mRNA expression.
Conclusions: These data indicate that sKlotho levels are not affected in type 2 diabetes patients with and without
MVD. Furthermore, hyperglycemia per se does not affect renal Klotho production. As type 2 diabetes does not alter
sKlotho levels, sKlotho does not seem to play a major role in the pathogenesis of MVD in type 2 diabetes.
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Patients with type 2 diabetes have a high incidence
of macrovascular disease (MVD), including coronary ar-
tery disease (CAD) and peripheral artery disease (PAD)
[1]. The transmembrane protein αKlotho (referred to as
Klotho) is predominantly expressed in renal distal tubular
epithelial cells where it functions as an obligate co-receptor
with Fibroblast Growth Factor Receptor 1 (FGFR1) for
Fibroblast Growth Factor 23 (FGF23), a phosphaturic hor-
mone essential for maintaining mineral homeostasis [2]. In
mice, Klotho deficiency is associated with accelerated and
enhanced development of vasculopathy [3]. The extracel-
lular domain of Klotho can be cleaved and shed in the
circulation (i.e. soluble Klotho [sKlotho]) where it may
function as a vasculoprotective hormone possibly by en-
hancing endothelial function [4,5] or direct inhibition of
vascular calcification [6]. Recently, in agreement with
this, higher sKlotho levels appeared to be independently
associated with reduced prevalence of cardiovascular
disease [7]. Moreover, in patients with chronic kidney
disease (CKD) a graded reduction of urinary sKlotho
has been described starting at an early stage of CKD,
rendering sKlotho as a sensitive biomarker for early de-
tection of CKD [6,8]. Finally, a reduction in renal Klotho
gene expression has been observed in kidneys from pa-
tients with diabetic nephropathy [9].
Studies on sKlotho levels in diabetes are scarce and
inconclusive and data have been obtained using various
commercially available assays [10,11]. We need to in-
terpret these data with caution, because a reliable
ELISA-based assay to measure sKlotho levels has only
recently become available [12]. Nevertheless, reduced
sKlotho levels in type 2 diabetes could potentially be
used as a biomarker for cardiovascular risk, and there-
fore studies on this are warranted. In addition, given its
impact on both endothelial function and medial calcifi-
cation, sKlotho may be involved in the pathogenesis of
MVD in type 2 diabetes.
Against this background, in the current cross-sec
tional study we determined serum sKlotho levels in pa-
tients with type 2 diabetes with and without MVD, but
without diabetic nephropathy. In addition we inves-
tigated the potential effect of hyperglycemia on renal
Klotho expression. The following hypotheses were
tested: 1) type 2 diabetes is associated with reduced
sKlotho levels, particularly in patients with MVD and
2) hyperglycemia reduces renal Klotho expression.
To this end, sKlotho ELISAs on patient sera were
performed as well as in vivo mouse and in vitro cell
culture experiments. Our data indicate that sKlotho
levels are not affected in type 2 diabetic patients with
and without MVD. This is supported by our in vivo
and in vitro data showing that hyperglycemia per se
does not affect renal Klotho production.Methods
Study population
Patients with type 2 diabetes and non-diabetic subjects
with and without MVD were included in this study. In-
dividuals included are a subset of subjects on which we
recently reported [13]. Patients were assigned to the fol-
lowing groups: diabetes, no MVD (n = 11); diabetes with
CAD (n = 12); diabetes with PAD (n = 12); no diabetes
with CAD (n = 13); and no diabetes with PAD (n = 14).
Diagnosis of type 2 diabetes was based on criteria
recommended by the WHO (http://whqlibdoc.who.int/
publications/2006/9241594934_eng.pdf ). In addition, age
and sex-matched healthy control subjects (n = 15) were
included in the study. Diagnosis of CAD was based on
prior myocardial infarction (> 6 months), or of evidence
of significant coronary artery stenosis during angiog-
raphy. PAD was diagnosed based on a history of claudi-
cation or rest pain and assessed with bilateral peripheral
arterial foot pulse examination and duplex ultrasonog-
raphy. Patients with clinical evidence of both CAD and
PAD were excluded from the study. Patients with clinic-
ally documented nephropathy (with eGFR < 60 mL/min/
1.73 m2 or macroalbuminuria) were excluded from the
study to exclude the potential confounding effect of kid-
ney disease on sKlotho levels and presence of arterial
disease. Additional exclusion criteria were: retinopathy,
auto-immune diseases, neoplasms, acute or chronic infec-
tions, recent (< 6 months) surgery, age >80 yrs, hemodialysis
and use of immunosuppressive agents. Participants were
screened for cardiovascular risk factors including smoking,
hypertension and BMI. In addition, laboratory measure-
ments for glucose, HbA1c, lipid levels, blood urea nitro-
gen (BUN), serum creatinine, serum phosphate and serum
calcium were performed. Estimated glomerular filtration
rate (eGFR, mL/min per 1.73 m2) was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [14]. Blood samples were obtained by
venipuncture and collected in EDTA vacutainers for
plasma isolation and in coagulation tubes for isolation of
serum. Coagulation tubes were allowed to clot for a mini-
mum of 30 minutes at room temperature before serum
separation. Blood samples were centrifuged and plasma or
serum was collected and stored at −80°C until further ana-
lysis. All participants gave written informed consent. The
study protocol was approved by the local ethics committee
of the University Medical Center Groningen (METc:
2008/335) and investigations were carried out in accord-
ance with the principles of the Declaration of Helsinki.
Spontaneous diabetic Ins2Akita mice
Spontaneous diabetic heterozygous Ins2Akita+/− (Ins2Akita)
mice, purchased from Jackson Laboratory (Charles River
Laboratories, Sulzfeld, Germany), were bred at the animal
facility of the University Hospital Mannheim, University of
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Ins2Akita−/− littermates served as control. Mice were
housed in groups in cages with free access to standard
food and water under a 12-h light and 12-h dark
rhythm. Both male and female mice were used in this
study. Glucose levels and body weight were monitored
consecutively every other week, and HbA1c concentration
was determined by affinity chromatography at the end of
the study (MicromatII; Bio-Rad Laboratories, Munich,
Germany). Insulin was occasionally given to individual
diabetic mice to prevent critical weight loss. After 3 and
8 months of diabetes, kidneys were harvested under deep
anesthesia and immediately frozen at −80°C until further
analysis. Animal experiments were performed according
to the ‘Principles of laboratory animal care’ (NIH publica-
tion no. 85–23, revised 1985; http://grants1.nih.gov/
grants/olaw/references/phspol.htm) and were approved by
the Institutional Animal Care and Use Committee of the
University of Heidelberg.
Klotho and cFGF23 ELISA
sKlotho levels were determined in human serum using
a sandwich ELISA (Immuno-Biological Laboratories,
Takasaki, Japan) with an intra-assay coefficient of vari-
ation (cv) and interassay cv of < 5% and < 8% respec-
tively. c-Terminal FGF23 levels were determined in
plasma using a sandwich ELISA (Immutopics, San
Clemente CA) with an intra-assay cv of < 5% and
interassay cv of < 16% [15]. Both assays were performed
according to the manufacturer’s instructions. All samples
and standards were measured in duplicate. Absorbance
values were measured at 450 nm with a VarioSkan
Microplate Reader (Thermo Scientific, Landsmeer, The
Netherlands).
Primary tubular epithelial cell (TEC) culture
TECs were isolated from a segment of healthy renal cor-
tex, which was obtained from a nephrectomized kidney
with renal cell carcinoma. The segment was taken distal
from the tumor. The segment was cut into 1 mm3
pieces, washed in HBSS and subsequently placed in a
T25 culture flask coated with FBS. The fragments were
allowed to attach by putting the flask upside down for
1 hour at 37°C, 5% CO2. Next, 2.5 mL TEC medium
(DMEM/Ham-F12 1:1 supplemented with Penicillin/
Streptomycin, 25 mM HEPES, 2 mM L-glutamine,
insulin-transferrin-sodium selenite supplement, hydro-
cortisone (36 ng/ml), epidermal growth-factor (10 ng/
ml) and 5% heat-inactivated FBS) was gently added to
the flask which was then put right-side-up in the incuba-
tor. Explant cultures were left untouched for 3 days after
which 1 mL medium was added every 2–3 days. After
21 days, detached floating tissue fragments were removed
and adherent TECs were detached using Trypsin/EDTAand seeded in new flasks (passage 1). Medium wash
refreshed every 2–3 days.
Immunostaining
Immunostaining was performed on TECs (passage 2)
cultured in 8-well permanox chamber slides (Nalge
Nunc, Creek Drive, USA). Subconfluent monolayers
were washed with PBS and fixed for 15 minutes (room
temperature) with 2% paraformaldehyde in PBS. After
fixation, cells were washed twice with PBS and subse-
quently permeabilized in PBS/0.05% Triton for 3 minutes
and washed with PBS. Next, cells were incubated with
primary antibodies diluted in PBS/1% BSA for 60 mi-
nutes at room temperature. The following primary anti-
bodies were used: mouse anti-cytokeratin (Clone AE1/
AE3, DAKO, Glostrup, Denmark), mouse anti-cytokeratin
7 (Clone OV-TL 12/30, DAKO), mouse anti-epithelial
membrane antigen (EMA, Clone E29, DAKO), and rat
anti-Klotho (Clone KM2076, Transgenic Inc., Tokyo,
Japan). For immunofluorescence, cells were subsequently
incubated (30 minutes, room temperature) with species-
specific AlexaFluor®555 conjugated-secondary antibodies
(Life Technologies) diluted in PBS/1% BSA containing
DAPI for nuclear counterstaining. Slides were mounted
with Aqua PolyMount (Polysciences, Warrington, USA).
Images were acquired with a Zeiss AxioObserver Z1
inverted microscope equipped with TissueFAXS acqui-
sition software (Tissuegnostics, Vienna, Austria). For
Klotho immunohistochemistry, cells were incubated for
30 minutes at room temperature with horseradish per-
oxidase (HRP)-conjugated rabbit anti-rat antibodies,
which was followed by incubation with HRP-conjugated
goat anti-rabbit antibodies for 30 minutes at room
temperature. Peroxidase staining reaction was devel-
oped with 3-Amino-9-ethylcarbazole (AEC) as sub-
strate. Nuclear counterstaining was performed with
Mayer’s haematoxilin. Slides were mounted with Kai-
ser’s glycerin and images were aquired with an Olympus
BX50 microscope.
TEC stimulation and quantitative immunofluorescence
For in vitro stimulation experiments, TECs were seeded
at a density of 2x104 cells/cm2 in TEC medium con-
taining 0.5% FBS and were allowed to attach for
24 hours. For hyperglycemic conditions, TECs were sub-
sequently incubated for 96 hours in TEC medium
containing 0.5% FBS and 7.8 mM (standard concentra-
tion), 15 mM or 30 mM D-glucose. Medium was
refreshed every day. For stimulation with human serum,
cells were seeded as described above. After 24 hours at-
tachment the medium was replaced with TEC medium
containing 5% 0.22 μm filtered human serum derived
from 5 diabetic patients without MVD (average serum
glucose level 6.5 mmol/L) or 5 healthy control subjects
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incubated for 96 hours and medium was replaced every
day. Next, cells were either fixed in 2% paraformalde-
hyde for quantitative immunofluorescence or lysed in
RLT buffer (Qiagen, Venlo, the Netherlands) and stored
in −80°C for subsequent RNA isolation.
To quantify Klotho protein expression in vitro, we
performed Klotho immunofluorescence asdescribed
above followed by quantitative TissueFAXS analysis.
The total number of cells per mm2 surface area as well
as the percentage Klotho+ cells and staining intensity
under each experimental condition were determined
using the TissueFAXS system (Tissuegnostics, Vienna,
Austria), as described before [13]. To quantify the rela-
tive Klotho staining intensity, the mean fluorescence of
intensity ratio (MFIR) was calculated by dividing the
mean fluorescence intensity (MFI) of Klotho positive
cells by the MFI of negative controls.
Quantitative real-time PCR
Total RNA was isolated from mouse kidneys and human
TECs using the RNeasy Micro kit (Qiagen) according to
the manufacturer’s instructions. The RNA quantity was
measured with a Nanodrop spectrophotometer. For cDNA
synthesis, 1 ug RNA was converted to cDNA using Super-
Script II reverse transcriptase and random hexamere
primers (Life Technologies) according to the manufac-
turer’s instructions. Klotho mRNA expression was mea-
sured with a Taqman Gene expression assay (Applied
Biosystems, Carlsbad, USA) using exon junction spanning
primers for human Klotho (assay Hs00183100_m1) and
mouse Klotho (assay Mm00502002_m1). For normalization
of mouse Klotho expression, B2M (Mm00437762_m1) was
included as a housekeeping gene. For normalization of hu-
man Klotho expression, HPRT was included as a house-
keeping gene using in house developed primers (FW:
GGCAGTATAATCCAAAGATGGTCAA; REV: GTCTGG
CTTATATCCAACACTTCGT) and probe (CAAGCTTG
CTGGTGAAAAGGACCCC) (Eurogentec Nederland B.
V., Maastricht, The Netherlands). PCR reactions were
performed on a LightCycler 480 II Real-Time PCR Sys-
tem (Roche Applied Sciences, Penzburg, Germany).
Gene expression was analyzed with LightCycler 480
Software release 1.5.0 (Roche). To obtain the ΔCt, the
Ct values of the respective housekeeping gene were
subtracted from the Klotho Ct value. We used the com-
parative Ct method (2-ΔCt method) to calculate relative
Klotho gene expression.
Statistical analysis
Normal distribution of continuous variables was tested
with the Shapiro-Wilk test. For normally distributed data,
the unpaired two-tailed Student’s t-test was used for com-
parisons between two groups and the one-way ANOVAwith Bonferroni post-hoc was used for comparisons be-
tween three or more groups. For non-normally distrib-
uted data the non-parametric Mann–Whitney U test
was used for comparisons between two groups. For
comparisons between three or more groups of non-
normally distributed data, the Kruskall-Wallis one-way
analysis of variance was performed followed by pairwise
comparisons using the Mann–Whitney U test with
Bonferroni multiple testing correction. Dichotomous pa-
tient characteristics were compared with the χ2 test. Dif-
ferences were considered significant at p < 0.05. Normally
distributed data are reported as mean ± SEM, non-
normally distributed data are reported as medians with
interquartile range and categorical variables are presented
as percentages. All data were analyzed using SPSS (version
20) and GraphPad Prism software (version 5).
Results
Patient characteristics
Characteristics of individuals included in this study are
shown in Table 1. Diabetes duration of diabetic patients
was 14.1 ± 0.9 years with HbA1c levels of 7.7 (6.8-8.5)%
(60.1 (50.8-69.4) mmol/mol) (compared with 5.8 (5.5-
6.0)% (39.3 (36.6-42.1) mmol/mol) in non-diabetic sub-
jects, p < 0.01). No differences in glycemic control be-
tween subgroups of diabetic patients were observed
(Table 1). There was no statistically significant difference
in renal function between diabetic patients (sCr: 68 (81–
80) μmol/L, eGFR: 89 (79–96) mL/min/1.73 m2) and
non-diabetic subjects (sCr: 76 (64–83) μmol/L, eGFR: 94
(79–100) mL/min/1.73 m2) and no significant differ-
ences were observed between subgroups (Table 1). In
line with this, BUN levels were similar among all groups.
Additionally, no significant differences in serum phos-
phate and calcium levels were observed.
Serum sKlotho and plasma cFGF23 levels
Serum sKlotho concentration was measured with
ELISA (Table 1). No difference in sKlotho levels be-
tween healthy control subjects and diabetic patients
was observed (Figure 1A). Also, no difference in serum
sKlotho levels between diabetic patients with and with-
out MVD was detected (Figure 1B). Similarly, MVD in
non-diabetic subjects was not associated with reduced
serum sKlotho levels either (Figure 1C). Furthermore,
sKlotho levels were not significantly associated with
serum creatinine levels or eGFR in diabetic and non-
diabetic subjects. Reduced renal Klotho expression (in-
dependent of sKlotho levels) might be associated with a
compensatory increase in circulating FGF23, due to
FGF23 resistance. However, plasma cFGF23 levels did
not significantly differ between diabetic patients and
non-diabetic subjects and no differences were observed
among the different subgroups (Table 1). Furthermore,
Table 1 Patient characteristics
Diabetes No Diabetes
No MVD (n = 11) CAD (n = 12) PAD (n = 12) Healthy control (n = 15) CAD (n = 13) PAD (n = 14) p value
Demographics
Age (years) 56.0 (50.0-63.0)a 65.5 (62.0-71.0) 70.5 ± (63.5-74.0) 55.0 (53.0-56.0)b 57.0 (53.0-71.0) 59.5 (53.0-64.0) p < 0.05
Sex (% male) 5 (46) 6 (50) 6 (50) 8 (53) 9 (69) 8 (57) NS
Body mass index (kg/m2) 32.6 ± 2.6c 32.2 ± 2.1c 28.5 ± 3.1 24.5 ± 0.8 27.1 ± 1.0 23.6 ± 0.9 p < 0.001
Diabetes duration (years) 14.2 ± 1.0 16.8 ± 1.5d 11.3 ± 1.6 - - - p < 0.05
Smoking (%) 3 (27) 1 (8) 2 (17) 2 (13) 5 (39) 8 (57)i p < 0.05
Metabolic variables
WBC count (106/mL) 7.9 (5.7-11.9) 7.0 (5.8-7.4) 8.7 (7.4-10.2) 5.6 (4.4-6.4)e 5.5 (5.1-6.8) 8.1 (5.9-9.2) p < 0.05
Glucose (mmol/L) 7.1 ± 0.4f 9.7 ± 1.5f 9.5 ± 1.5f 5.3 ± 0.1 - 6.0 ± 0.6 p < 0.001
HbA1c - (%) 7.9 (7.2-9.8)f 8.3 (6.8-8.5)f 7.4 (6.6-8.4)f 5.6 (5.5-5.9) 5.8 (5.6-6.0) 5.6 (5.5-6.0) p < 0.001
- (mmol/mol) 62.8 (54.6-83.1)f 66.7 (50.8-69.4)f 57.4 (48.6-68.3)f 37.7 (36.6-41.0) 39.9 (37.7-42.1) 37.7 (36.1-42.1) p < 0.001
Cholesterol (mmol/L) 4.2 (3.6-4.7) 4.3 (3.8-5.2) 4.3 (3.8-4.5) 5.8 (5.0-6.3)g 4.0 (3.6-4.5) 4.4 (3.4-5.9) p < 0.01
Triglyceriden (mmol/L) 1.6 (1.1-2.1) 2.1 (1.7-3.0) 1.9 (1.3-2.2) 1.5 (1.0-1.8) 1.4 (0.9-2.1) 1.9 (0.9-2.8) NS
HDL-cholesterol (mmol/L) 1.3 (1.2-1.4) 1.1 (1.1-1.3)h 1.1 (0.9-1.4) 1.5 (1.4-1.9) 1.2 (1.2-1.5) 1.3 (1.0-1.7) p < 0.05
LDL-cholesterol (mmol/L) 2.3 (1.9-2.6) 2.1 (2.0-3.1) 2.1 (1.6-2.7) 3.6 (3.3-4.0)g 2.2 (1.9-2.8) 2.3 (1.7-3.5) p < 0.01
Creatinine (μmol/L) 64.5 (53.5-76.0) 68.5 (66.0-79.0) 68.0 (57.0-89.0) 75.0 (63.0-82.0) 80.0 (75.0-84.0) 71.0 (63.0-79.0) NS
eGFR (mL/min/1.73 m2) 97.3 (87.0-107.4) 86.1 (82.7-90.3) 80.8 (73.2-90.4) 94.9 (87.1-97.9) 90.0 (66.6-99.1) 99.7 (80.2-101.5) NS
BUN (mmol/L) 6.2 (4.7-7.0) 6.5 (5.5-7.4) 7.0 (5.9-7.9) 6.2 (5.5-7.0) 6.3 (5.9-6.9) 6.2 (4.4-6.5) NS
Phosphate (mmol/L) 1.1 ± 0.1 1.2 ± 0.1 1.4 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 NS
Calcium (mmol/L) 2.7 (2.5-2.8) 2.9 (2.5-3.4) 2.9 (2.4-3.2) 2.7 (2.3-2.9) 2.9 (2.6-3.1) 2.9 (2.5-3.3) NS
sKlotho (pg/mL) 581.4 (496.8-651.9) 561.0 (463.2-747.0) 493.7 (287.8-777.7) 434.7 (345.8-662.9) 490.5 (349.0-549.4) 518.9 (401.5-570.5) NS
FGF23 (RU/mL) 131.0 (118.5-147.0) 117.5 (106.0-256.0) 149.0 (120.0-237.0) 99.5 (87.0-119.0) 97.0 (88.0-112.0) 121.0 (105.0-140.0) NS
Medication
Insulin (%) 10 (91) 11 (92) 8 (67) - - - NS
Oral glucose-lowering 6 (55) 8 (67) 10 (83) - - - NS
agents (%)
Statins (%) 7 (64) 11 (92) 10 (83) 1 (7)i 13 (100)i 10 (71) p < 0.001
ACE inhibitors (%) 7 (64) 5 (42) 7 (58) 1 (7)i 10 (77)i 6 (43) p < 0.01
Angiotensin II inhibitor (%) 2 (18) 4 (33) 1 (8) 0 (0) 1 (8) 2 (14) NS
Alpha blockers (%) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NS
Beta blockers (%) 1 (9) 7 (58) 3 (25) 1 (7)i 12 (92)i 3 (21) p < 0.001
Calcium antagonists (%) 4 (36) 7 (58)i 5 (42) 0 (0)i 1 (8) 3 (21) p < 0.01
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Table 1 Patient characteristics (Continued)
Diuretics (%) 6 (55) 9 (75)i 6 (50) 1 (7)i 4 (31) 3 (21) p < 0.01
Antiaggregants (%) 2 (18)i 9 (75) 7 (58) 0 (0)i 12 (92)i 11 (79)i p < 0.001
Anticoagulants (%) 1 (9) 0 (0) 1 (8) 0 (0) 2 (15) 1 (7) NS
Data are presented as percentage, or as mean ± SEM for normally distributed data, or as median (interquartile range) for skewed data as appropriate. Statistically significant with ANOVA compared with: adiabetes with
PAD. bdiabetes with CAD, diabetes with PAD. cno diabetes with PAD, healthy control. ddiabetes with PAD. ediabetes without MVD, diabetes with PAD, no diabetes with PAD. fall groups without diabetes. gdiabetes
without MVD, diabetes with PAD, no diabetes with CAD. hhealthy control. istatistically significant with χ2 test. NS: not significant.
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Figure 1 Klotho serum levels are not reduced in type 2 diabetes and MVD. (A) No differences in serum sKlotho levels are present between
healthy control subjects and type 2 diabetes patients with and without MVD. (B) Within type 2 diabetes patients, no difference in sKlotho levels
between patients with or without MVD is present. (C) Similarly, when comparing non-diabetic patients with MVD with healthy control subjects
no difference in sKlotho concentration was detected. Data are expressed as Tukey’s box-and-whisker plots.
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TEC phenotype
For in vitro studies on renal Klotho production primary
TECs were isolated, expanded and phenotyped. TECs
consisted of a morphologically heterogeneous cell popu-
lation consisting of cobblestone and elongated spindle-
shaped cells (Figure 2A). Most cells showed positive
staining with antibodies against pan-cytokeratin marker
AE1/3, indicating that TECs belong to the epithelial lineage
(Figure 2B). A smaller proportion of TECs expressed the
distal tubule markers cytokeratin 7 (Figure 2C) and EMA
(Figure 2D). TECs thus represent a mixture of different
renal tubular epithelial cell types. Strong positive im-Figure 2 TECs isolated from kidney explants express renal tubular ma
containing cells with heterogeneous morphology. Immunofluorescence rev
markers Pan-cytokeratin (AE1/3) (B), Cytokeratin 7 (CK7) (C) and Epithelial M
shown with immunofluorescence (E) and immunohistochemistry (F). Nucle
shown in red (AlexaFluor®555 for immunofluorescence and AEC for immun
Brightfield. Magnification: 200x; magnification, insets: 630x.munostaining for Klotho was observed in a minority of cells
(Figure 2E,F).
Effect of hyperglycemia and type 2 diabetic
patient-derived serum on renal Klotho production
Next, we analyzed whether hyperglycemia affects renal
Klotho production in vitro. Additionally, to investigate if
other circulating factors in diabetic patients influence
renal Klotho production, TECs were cultured in the
presence of serum from diabetic patients or healthy con-
trol subjects. Quantitative immunofluorescence was used
to quantify the numbers of Klotho-expressing cells as
well as the expression level (Figure 3A,B). Exposure to
30 mM glucose decreased the total number of TECs
(Figure 3C). However, the percentage of Klotho+ cellsrkers and produce Klotho. (A) Cultured TECs form a monolayer
ealed extensive immunoreactivity with antibodies against epithelial
embrane Antigen (EMA) (D). Moreover, TECs produce Klotho as
ar staining is shown in blue while positive staining with antibodies is
ohistochemistry). Arrows indicate Klotho positive epithelial cells. BF:
Figure 3 Hyperglycemia and diabetes patient-derived serum do not alter Klotho production in TECs in vitro. (A, B) Representative
immunofluorescence images of TECs stained for Klotho and corresponding scatterplots produced by quantitative TissueFAXS analysis. (A)
Negative control staining (primary antibody omitted) with corresponding scatterplot. (B) Immunofluorescence image of TECs cultured in the
presence of 30 mM glucose, stained for Klotho, with corresponding scatterplot. (C) The total number of TECs in vitro was significantly lower when
cells were incubated with medium containing 30 mM glucose compared with lower glucose concentrations. However, there was no effect of
hyperglycemic culture conditions on the percentage of Klotho+ cells (D) or the Klotho staining intensity (E). In addition, serum derived from
diabetic subjects did not affect the total number of cells (F), percentage of Klotho+ cells (G), the Klotho staining intensity (H) or the relative level
of Klotho mRNA expression (I) compared with serum derived from healthy control subjects. (J) No difference in renal Klotho mRNA expression
was observed between hyperglycemic Ins2Akita and normoglycemic control mice. However, a significant reduction in renal Klotho mRNA
expression was detected in 8 months old mice compared with 3 months old mice, independent of the presence of diabetes. Data are expressed
as scatterplots with the horizontal bar representing the median; *p < 0.05.
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cells (Figure 3E) was not altered after exposure to high
glucose. Quantitative real-time PCR confirmed the ex-
pression of Klotho mRNA in TECs. However, Klotho
mRNA expression was not altered after exposure to high
glucose (data not shown). These data suggest that hyper-
glycemia does not influence renal Klotho production.
Similar results with regard to total cell number (Figure 3F),percentage Klotho+ cells (Figure 3G), Klotho staining in-
tensity (Figure 3H) or Klotho gene expression (Figure 3I)
were obtained after culture of TECs in the presence of
serum derived from diabetic patients.
Renal Klotho mRNA expression in diabetic Ins2Akita mice
To study whether hyperglycemia affects renal Klotho
expression in vivo, kidneys from 3 and 8 months
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Ins2Akita mice had significantly increased HbA1c levels at
both 3 months (13.1 (12.6-13.3)% (119.7 (114.2-121.9)
mmol/mol) vs. 6.2 (6.0-6.6)% (44.3 (42.1-48.6) mmol/mol),
p < 0.0001) and 8 months (10.9 (7.9-14.7)% (95.6 (62.3-
137.2) mmol/mol) vs. 6.5 (5.4-6.6)% (47.5 (35.5-48.6)
mmol/mol), p < 0.05) when compared with age-matched
wild-type control mice, confirming a severe hyperglycemic
state in diabetic Ins2Akita mice. No difference in renal
Klotho gene expression in 3 and 8 months hyperglycemic
Ins2Akita mice was observed when compared with age-
matched normoglycemic control mice (Figure 3J). Ageing
was clearly associated with significantly reduced Klotho
gene expression (Figure 3J).
Discussion
This study demonstrates that circulating sKlotho levels
are similar in patients with type 2 diabetes and healthy
individuals in the absence of nephropathy. In addition,
no difference in sKlotho levels was observed between
MVD patients and healthy control subjects, independent
of the presence of diabetes. The lack of a decline in
sKlotho in diabetic subjects with or without MVD can
have several explanations. First, the null hypothesis
might be true, implying that changes in sKlotho levels
are not involved in the pathogenesis in MVD, independ-
ent from age or kidney function. Moreover, the wide-
spread use of ACE-inhibitors and angiotensin receptor
blockers in the diabetic subjects may have counter-
balanced a presumed negative effect of diabetes on
Klotho production [16]. Finally, it has been shown that
insulin promotes cleavage of Klotho from the plasma
membrane by ADAM10 and ADAM17, generating
sKlotho [17]. Therefore, exogenously administered insu-
lin in diabetic patients might compensate diabetes in-
duced sKlotho depletion by increasing sKlotho shedding
from the cell membrane. Our in vitro data are however
not in favor of these explanations, but rather strengthen
our conclusion that diabetes does not influence renal
Klotho expression.
Our data are in contrast with results reported by
Semba et al. showing that the presence of CVD is inde-
pendently associated with reduced sKlotho levels [7]. A
potential explanation for this discrepancy might be that
in the present study only patients with isolated CAD or
PAD were included, while in the study by Semba et al.
CVD patients with stroke and heart failure were in-
cluded as well. Similar to our data, in the study by
Semba et al. neither CAD nor PAD were separately as-
sociated with lower sKlotho levels.
Dysregulation of the FGF23-Klotho axis contributes to
disturbed mineral homeostasis and as such might increase
cardiovascular risk in diabetes. Therefore, we additionally
measured cFGF23 levels in our cohort. However, likesKlotho, no differences in cFGF23 levels among the differ-
ent study groups were observed. In line with this, serum
calcium and phosphate levels were similar among all
groups.
Circulating sKlotho concentration may not necessar-
ily reflect total renal Klotho production, and despite
similar sKlotho levels in diabetic and non-diabetic indi-
viduals, membrane-bound renal Klotho expression
might be affected as a consequence of diabetes. Studies
on this would have required kidney biopsy in our co-
hort. As a surrogate we performed in vitro experiments
with TECs exposed to high glucose. In addition, we
measured renal Klotho gene expression in long-term
hyperglycemic Ins2Akita mice. Both the in vitro and
in vivo mouse experiments revealed that renal Klotho
production is not affected by hyperglycemia per se.
Furthermore, the in vitro data suggest that circulating
factors other than glucose in type 2 diabetes (such as
glycated proteins or proinflammatory cytokines) do not
influence renal Klotho production, as no difference in
Klotho production between TECs exposed to serum
derived from diabetic patients and healthy control sub-
jects was observed.
Interpretation of results from different studies on sKlotho
is still complicated by the fact that different assays (which
are not all reliable and validated) are being used by differ-
ent investigators. The results described here are in line
with a recent study by Seiler et al. using the same Klotho
assay, which showed that sKlotho levels are in fact not
associated with deteriorated kidney function in CKD pa-
tients, and have poor predictive value for all-cause mortal-
ity after 2-years follow up. Furthermore, low sKlotho
serum levels were not associated with an increased preva-
lence of diabetes in this study [18].Limitations
The present study is somewhat limited by a small sam-
ple size per group which may have obscured small differ-
ences in sKlotho levels between groups. Our in vitro
studies were limited by the measurement of total cellular
Klotho mRNA and protein under normo-and hypergly-
cemic culture conditions. We cannot exclude that the
cleavage and excretion of sKlotho is affected by in-
creased glucose levels in vitro.Conclusions
Despite the recent interest in sKlotho as a biomarker for
renal and cardiovascular disease, our study did not pro-
vide a rationale for using sKlotho levels as biomarker for
MVD in type 2 diabetic patients and non-diabetic sub-
jects in the absence of nephropathy. Based on our data,
a major role of sKlotho in the pathophysiology of MVD
in diabetes is unlikely.
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